rs1524107 — IL6

Intronic IL6 variant tagging a low-producing haplotype — the T allele is protective against diabetic nephropathy and severe acute inflammation

See your personal result for IL6

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL-6 and the Inflammaging Switch — A Haplotype That Quiets the Fire

Interleukin-6 (IL-6) is the central cytokine of inflammaging11 inflammaging
the chronic, low-grade sterile inflammation that accumulates with age and underlies most age-related diseases — first described by Franceschi et al. in 2000. Serum IL-6 concentrations rise two- to four-fold between age 20 and 80 in healthy adults, and this rise is not incidental — it predicts cardiovascular events, cognitive decline, muscle loss, frailty, and all-cause mortality better than almost any other biomarker. rs1524107 is an intronic variant in the IL6 gene (chromosome 7p15.3) that acts as a tag for one of the most functionally important haplotypes in the gene's regulatory architecture.

The Mechanism

rs1524107 sits in intron 2 of IL6 at GRCh38 position 22,728,600, where the gene runs along the plus strand. The variant itself is intronic — it does not change an amino acid — but it is in high linkage disequilibrium22 linkage disequilibrium
a statistical measure of how often two alleles are inherited together; r²>0.8 means the alleles are nearly always co-inherited (r²≈0.92) with the promoter variant rs1800796 and with rs2066992 in intron 4. Together these three SNPs define a haplotype tagged rs1800796-C / rs1524107-T / rs2066992-T that is common in East Asia (>75% frequency) but rare in Europeans (~5%).

Lo et al. 2021 in mBio33 Lo et al. 2021 in mBio
A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19 showed that the T-allele haplotype disrupts a conserved CTCF44 CTCF
CCCTC-binding factor, a master architectural protein that organises chromatin loops and regulates gene expression binding site at an intronic enhancer of the IL6 antisense lncRNA IL-6-AS1. Loss of this CTCF anchor reduces the chromatin looping that normally amplifies IL6 transcription during inflammatory stimuli. Cells from haplotype carriers respond poorly to LPS and viral challenge — producing less IL-6 — which protects against cytokine-storm hyperinflammation.

The Evidence

Alzheimer's disease: Lai et al. 201255 Lai et al. 2012
Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease. J Neuroinflammation, 9:21 recruited 266 Alzheimer's patients and 444 controls from Taiwan. Carriers of the rs1524107 C allele (CC+CT vs. TT) had an adjusted odds ratio of 0.60 (95% CI 0.41–0.89) for late-onset AD — meaning the C allele was protective in this East Asian sample where TT is the predominant genotype.

Diabetic nephropathy: Luo et al. 201666 Luo et al. 2016
Diabetes/Metabolism Research and Reviews 33(3) followed 568 Chinese type 2 diabetic patients for ~5 years. The CC genotype at rs1524107 (r²=0.92 with rs1800796) was significantly associated with more rapid nephropathy progression and lower nephropathy-free survival.

Severe acute inflammation: The mBio study (Lo et al. 2021, n=105 COVID-19 patients) found that the ancestral C allele at rs1524107 was overrepresented in severe cases (37.1% vs. 22.9%, P=0.029). Homozygous C-T-T haplotype carriers had OR=0.256 (95% CI 0.088–0.739) for severe disease — a 74% relative risk reduction.

Inflammaging and mortality: Harris et al. 199977 Harris et al. 1999
JAMA showed that the highest IL-6 quartile had 4.6-fold higher mortality over 4.5 years in adults over 70.

Practical Actions

Because rs1524107 tags an IL-6 regulatory haplotype rather than a coding change, the actionable lever is modulating IL-6 production through lifestyle and targeted supplementation. Chronic aerobic exercise is the strongest non-pharmacological tool for reducing resting IL-6: consistent moderate-intensity training lowers basal circulating IL-6 by 10–30% in older adults. Dietary omega-3 fatty acids (EPA/DHA) suppress NF-κB-driven IL-6 transcription at doses of 2–4 g/day. Mediterranean-style dietary patterns reduce IL-6 — but given the project ban on generic advice, the specific actionable items here are testing serum IL-6 directly and supplementing with compounds with documented IL-6-lowering pharmacology (omega-3, curcumin with piperine).

For the CC genotype in East Asian populations (or Europeans homozygous for the common C allele), the most important insight is that chronic IL-6 elevation is not inevitable: it is a modifiable risk mediated partly by genetics and substantially by adiposity, physical activity, and sleep quality.

Interactions

rs1524107 is in high LD with rs1800796 (the -572G/C promoter variant, r²≈0.92) and rs2066992 — any association seen for rs1524107 reflects the combined haplotype effect rather than an independent functional role. The related promoter variant rs1800795 (-174G/C) is a distinct functional variant in stronger LD within European populations. See rs1800795 for the European-centric IL-6 promoter effect on exercise physiology and cardiovascular risk. The combined picture is that IL6 harbours multiple semi-independent regulatory variants: -174 (rs1800795) drives European IL-6 variation; the intronic C-T-T haplotype (tagged by rs1524107) dominates in East Asian populations but has relevance globally through IL-6-AS1 regulation.

Genotype Interpretations

What each possible genotype means for this variant.

TT Protective Low-IL-6 Haplotype Beneficial

Both copies carry the low-producing IL-6 haplotype allele

You carry two copies of the T allele at rs1524107, which tags the low-producing IL-6 haplotype (rs1800796-C / rs1524107-T / rs2066992-T). This genotype is extremely rare in European populations (~1%) but is the majority genotype in East Asian populations (~57% in Chinese cohorts). Homozygous T-T carriers showed a 74% relative reduction in risk of severe inflammatory illness (OR=0.256 in the COVID-19 severity study), lower progression of diabetic nephropathy, and a more blunted IL-6 response to inflammatory stimuli.

CT One Protective Allele Intermediate

One copy of the protective low-IL-6 allele, one high-expression copy

You carry one C allele and one T allele at rs1524107. About 19% of people globally share this genotype, though it is far more common in East Asian populations (the T allele reaches ~75% frequency in East Asia but only ~5% in Europeans). Heterozygotes have an intermediate IL-6 regulatory tone. Clinical risk sits between the two homozygous states.

CC Higher IL-6 Haplotype High Risk

Both copies carry the ancestral high-expression IL-6 allele

The CC genotype tags the common ancestral IL6 haplotype where the CTCF binding site at the intronic enhancer is intact, supporting normal IL-6 amplification loops during inflammatory challenge. Under ordinary healthy conditions this makes little difference. Studies in East Asian populations found the CC genotype associated with significantly faster diabetic nephropathy progression. In a COVID-19 severity study, the C allele was overrepresented in severe cases (37.1% vs. 22.9% in mild/moderate; P=0.029), suggesting the high-IL-6 haplotype amplifies hyperinflammatory responses.